Spinraza – Canada – final drug review | High, apple pie, in the sky, hopes
Ionis's Spinraza Still Bests Novartis's Zolgensma (NYSE:NVS) | Seeking Alpha
Biogen and Ionis Pharmaceuticals: A Message to the SMA Community - Muscular Dystrophy Association
Threats to Spinraza are mounting, but Biogen still has cards to play | Evaluate
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy | NEJM
Combinatorial treatment for spinal muscular atrophy - Poletti - 2020 - Journal of Neurochemistry - Wiley Online Library
An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials | SpringerLink
Drug Trials Snapshots: SPINRAZA | FDA
Clinical Trials for Spinal Muscular Atrophy - Cure SMA
Later-Onset SPINRAZA® (nusinersen) Efficacy | HCP
Drug Trials Snapshots: SPINRAZA | FDA
Later-Onset SPINRAZA® (nusinersen) Efficacy | HCP
New Results From Landmark NURTURE Study Show That
Later-Onset SPINRAZA® (nusinersen) Efficacy | HCP
SMA treatment: Novartis and Biogen face lost market opportunities
Later-Onset SMA (Types 2 & 3)| SPINRAZA® (nusinersen)
Higher-dose Spinraza SMA Trial Now Enrolls After No Safety Issues Found
Risdiplam trials: exciting early results in Firefish – TreatSMA
Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden | SpringerLink
Biogen's Spinraza scores later-onset SMA data for stepped-up push with payers | Fierce Pharma
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study - Neuromuscular Disorders
